244 related articles for article (PubMed ID: 31176366)
1. CD45RA
Kunert A; Basak EA; Hurkmans DP; Balcioglu HE; Klaver Y; van Brakel M; Oostvogels AAM; Lamers CHJ; Bins S; Koolen SLW; van der Veldt AAM; Sleijfer S; Mathijssen RHJ; Aerts JGJV; Debets R
J Immunother Cancer; 2019 Jun; 7(1):149. PubMed ID: 31176366
[TBL] [Abstract][Full Text] [Related]
2. Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer.
Ottonello S; Genova C; Cossu I; Fontana V; Rijavec E; Rossi G; Biello F; Dal Bello MG; Tagliamento M; Alama A; Coco S; Boccardo S; Vanni I; Ferlazzo G; Moretta L; Grossi F; Mingari MC; Carrega P; Pietra G
Front Immunol; 2020; 11():125. PubMed ID: 32117275
[TBL] [Abstract][Full Text] [Related]
3. Tumor mutational load, CD8
Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic and functional characterizations of CD8
Zhang Y; Li W; Zhai J; Jin Y; Zhang L; Chen C
Exp Cell Res; 2022 Aug; 417(1):113212. PubMed ID: 35588796
[TBL] [Abstract][Full Text] [Related]
5. CD28/PD1 co-expression: dual impact on CD8
Palermo B; Franzese O; Frisullo G; D'Ambrosio L; Panetta M; Campo G; D'Andrea D; Sperduti I; De Nicola F; Goeman F; Gallina F; Visca P; Facciolo F; Nisticò P
J Exp Clin Cancer Res; 2023 Oct; 42(1):287. PubMed ID: 37898752
[TBL] [Abstract][Full Text] [Related]
6. Differentiation of human CD8(+) T cells from a memory to memory/effector phenotype.
Tomiyama H; Matsuda T; Takiguchi M
J Immunol; 2002 Jun; 168(11):5538-50. PubMed ID: 12023349
[TBL] [Abstract][Full Text] [Related]
7. The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC.
Mazzaschi G; Facchinetti F; Missale G; Canetti D; Madeddu D; Zecca A; Veneziani M; Gelsomino F; Goldoni M; Buti S; Bordi P; Aversa F; Ardizzoni A; Quaini F; Tiseo M
Lung Cancer; 2019 Jan; 127():153-163. PubMed ID: 30642544
[TBL] [Abstract][Full Text] [Related]
8. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
Fehlings M; Jhunjhunwala S; Kowanetz M; O'Gorman WE; Hegde PS; Sumatoh H; Lee BH; Nardin A; Becht E; Flynn S; Ballinger M; Newell EW; Yadav M
J Immunother Cancer; 2019 Sep; 7(1):249. PubMed ID: 31511069
[TBL] [Abstract][Full Text] [Related]
9. Cartography of gene expression in CD8 single cells: novel CCR7- subsets suggest differentiation independent of CD45RA expression.
Monteiro M; Evaristo C; Legrand A; Nicoletti A; Rocha B
Blood; 2007 Apr; 109(7):2863-70. PubMed ID: 17148588
[TBL] [Abstract][Full Text] [Related]
10. Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell Lung Cancer Patients.
de Goeje PL; Poncin M; Bezemer K; Kaijen-Lambers MEH; Groen HJM; Smit EF; Dingemans AC; Kunert A; Hendriks RW; Aerts JGJV
Clin Cancer Res; 2019 Apr; 25(7):2219-2227. PubMed ID: 30642911
[TBL] [Abstract][Full Text] [Related]
11. Blood Predictive Biomarkers for Patients With Non-small-cell Lung Cancer Associated With Clinical Response to Nivolumab.
Agulló-Ortuño MT; Gómez-Martín Ó; Ponce S; Iglesias L; Ojeda L; Ferrer I; García-Ruiz I; Paz-Ares L; Pardo-Marqués V
Clin Lung Cancer; 2020 Jan; 21(1):75-85. PubMed ID: 31562055
[TBL] [Abstract][Full Text] [Related]
12. Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor.
Inomata M; Kado T; Okazawa S; Imanishi S; Taka C; Kambara K; Hirai T; Tanaka H; Tokui K; Hayashi K; Miwa T; Hayashi R; Matsui S; Tobe K
Anticancer Res; 2019 Dec; 39(12):6887-6893. PubMed ID: 31810958
[TBL] [Abstract][Full Text] [Related]
13. Identification of naive or antigen-experienced human CD8(+) T cells by expression of costimulation and chemokine receptors: analysis of the human cytomegalovirus-specific CD8(+) T cell response.
Wills MR; Okecha G; Weekes MP; Gandhi MK; Sissons PJ; Carmichael AJ
J Immunol; 2002 Jun; 168(11):5455-64. PubMed ID: 12023339
[TBL] [Abstract][Full Text] [Related]
14. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
15. Four functionally distinct populations of human effector-memory CD8+ T lymphocytes.
Romero P; Zippelius A; Kurth I; Pittet MJ; Touvrey C; Iancu EM; Corthesy P; Devevre E; Speiser DE; Rufer N
J Immunol; 2007 Apr; 178(7):4112-9. PubMed ID: 17371966
[TBL] [Abstract][Full Text] [Related]
16. Infection with cytomegalovirus but not herpes simplex virus induces the accumulation of late-differentiated CD4+ and CD8+ T-cells in humans.
Derhovanessian E; Maier AB; Hähnel K; Beck R; de Craen AJM; Slagboom EP; Westendorp RGJ; Pawelec G
J Gen Virol; 2011 Dec; 92(Pt 12):2746-2756. PubMed ID: 21813708
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients.
Osa A; Uenami T; Koyama S; Fujimoto K; Okuzaki D; Takimoto T; Hirata H; Yano Y; Yokota S; Kinehara Y; Naito Y; Otsuka T; Kanazu M; Kuroyama M; Hamaguchi M; Koba T; Futami Y; Ishijima M; Suga Y; Akazawa Y; Machiyama H; Iwahori K; Takamatsu H; Nagatomo I; Takeda Y; Kida H; Akbay EA; Hammerman PS; Wong KK; Dranoff G; Mori M; Kijima T; Kumanogoh A
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282824
[TBL] [Abstract][Full Text] [Related]
18. Functional Heterogeneity of CD4
Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
Front Immunol; 2018; 9():2654. PubMed ID: 30505306
[TBL] [Abstract][Full Text] [Related]
19. Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer.
Basak EA; Koolen SLW; Hurkmans DP; Schreurs MWJ; Bins S; Oomen-de Hoop E; Wijkhuijs AJM; Besten ID; Sleijfer S; Debets R; van der Veldt AAM; Aerts JGJV; Mathijssen RHJ
Eur J Cancer; 2019 Mar; 109():12-20. PubMed ID: 30654225
[TBL] [Abstract][Full Text] [Related]
20. Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy.
Passaro A; Mancuso P; Gandini S; Spitaleri G; Labanca V; Guerini-Rocco E; Barberis M; Catania C; Del Signore E; de Marinis F; Bertolini F
Clin Transl Oncol; 2020 Apr; 22(4):603-611. PubMed ID: 31254252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
